TVAX Biomedical in the News Stay informed with the latest updates and developments from TVAX Biomedical. This collection of select news articles and press releases reflect the company’s progress and impact in the cancer therapeutics industry. June 29, 2023 BioSpace Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC View October 18, 2022 Company Press Release TVAX Biomedical Announces Receipt of $2 Million FDA Orphan Products Grant for Glioblastoma Study View April 30, 2020 Company Press Release TVAX Biomedical Receives Fast Track Designation from the FDA View March 11, 2019 Company Press Release TVAX Biomedical Names Wayne Carter as President and CEO View October 25, 2018 Company Press Release ELIAS Animal Health Announces Positive Results in Treatment of Osteosarcoma in Dogs View November 15, 2016 Company Press Release ELIAS Animal Health Adds Clinical Trial Site for ECI™ for the Treatment of Canine Osteosarcoma View August 24, 2016 Company Press Release ELIAS Animal Health Announces First Patient Enrolled in Clinical Trial for ECI™ for the Treatment of Canine B-Cell Lymphoma View June 29, 2023 BioSpace Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC View March 2015 Company Press Release TVAX secures $2 million financing for animal health subsidiary View June 2013 KC Business Getting Bang for the Buck in a Slow-Growth Economy View August 2012 Ingram’s Magazine Exploring New Frontiers View